Growing the love for investing
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
RSS Headlines
Fool UK
Recs
They are the hands down frontrunner in regards to treating the genotype 1 hep c patients.gilead is painting a picture of big success but if you look deeper they are using geno 2 when in reality, the hard to treat prevelent geno 1 null responders are being sent home without SVR 1 in 10 clears
I am currently enrolled in the stage III clinical trial (geno type 1), the results have been outstanding with very very minimal side effects, I am SVR 1 after 4 weeks, I did the only thing I could think of, I invested, As above Good Yield, lower PE relative to competitors, Respected Parent Corporate Culture, under the radar for now, when approval comes for the HPC this one is headed much much higher